CAR T cells have been very successful therapies for people with blood cancers who have not responded to other treatments. But now the FDA is concerned that the cellular therapy might be linked to the ...

PHILADELPHIA – The development of any type of second cancer following CAR T cell therapy is a rare occurrence, as found in an analysis of more than 400 patients treated at Penn Medicine, researchers ...

A large study by researchers at Stanford Medicine has found that the risk of secondary blood cancers after CAR-T cell therapy — a cell-based cancer treatment that exploded on the scene in 2017 as a ...

CAR-T cell therapy to treat blood cancers is safer than previously thought, with little risk that the immunotherapy will create secondary cancers, a new study finds. The U.S. Food and Drug ...

Please provide your email address to receive an email when new articles are posted on . Researchers did not observe insertional mutagenesis of CAR-T products among patients who developed secondary ...